BioMarin Pharmaceutical Inc. (BMRN) 2016年年度报告「NASDAQ」.pdf

1、 Morningstar Document Research FORM 10-KBIOMARIN PHARMACEUTICAL INC-BMRNFiled:February 27,2017(period:December 31,2016)Annual report with a comprehensive overview of the companyThe information contained herein may not be copied,adapted or distributed and is not warranted to be accurate,complete or t

2、imely.The userassumes all risks for any damages or losses arising from any use of this information,except to the extent such damages or losses cannot belimited or excluded by applicable law.Past financial performance is no guarantee of future results.ff UNITED STATESSECURITIES AND EXCHANGE COMMISSIO

3、NWashington,D.C.20549 Form 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2016OrTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to .Commission

4、 file number:000-26727 BioMarin Pharmaceutical Inc.(Exact name of registrant as specified in its charter)Delaware 68-0397820(State of other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)770 Lindaro StreetSan Rafael,California 94901(Address of principal executive offi

5、ces)(Zip Code)Registrants telephone number,including area code:(415)506-6700Securities registered pursuant to Section 12(b)of the Act:Title of Each Class Name of Each Exchange on Which RegisteredCommon Stock,$.001 par value The NASDAQ Global Select MarketSecurities registered under Section 12(g)of t

6、he Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether th